At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 61 enrolled
Drug / intervention
aripiprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
In Brief
A Phase 4 clinical trial evaluating aripiprazole and placebo for Schizophrenia. Completed, enrolled 61 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether aripiprazole augmentation is safe and effective in the treatment of clozapine-treated patients with refractory schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesSouth Korea
CollaboratorsKorea Otsuka Pharmaceutical Co., Ltd.
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedMay 2006
Primary CompletionDec 2006
Study CompletionFeb 2008
TodayJul 2026
First PostedMay 19, 2006
Enrollment StartDec 1, 2005
Primary CompletionDec 1, 2006
Study CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 20.1 years ago
Interventions
aripiprazoledrug
aripiprazole augmentation of clozapine
placebodrug
placebo